Prospective Evaluation of Speech Function Through Patient- and Parent-response Outcome Measurements in Velopharyngeal Insufficiency
Launched by UMEÅ UNIVERSITY · Apr 20, 2023
Trial Information
Current as of August 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how well speech function improves after surgery in children with a condition called velopharyngeal insufficiency (VPI), which often occurs in those born with cleft lip and/or palate. VPI makes it hard for children to close off the nasal passage when they talk, leading to problems with speech clarity and social interactions. The study aims to gather feedback from both the children undergoing surgery and their parents to better understand how effective the surgery is in improving speech.
To be eligible for this trial, children under 18 years old who have isolated or combined cleft palate and are scheduled for a specific type of surgery called pharyngeal flap surgery can participate. The study is currently recruiting participants across six specialized cleft centers in Sweden. Parents and their children who join the study will be asked to share their experiences and observations about speech changes after the surgery. This information will help doctors understand who benefits most from these surgical treatments and improve care for future patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All children \< 18 years of age with isolated or combined cleft palate that will undergo pharyngeal flap surgery due to velopharyngeal insufficiency, as well as their parents, in any of the 6 specialized cleft center in Sweden.
- Exclusion Criteria:
- • Cognitive impairment making it difficult to understand the study.
About Umeå University
Umeå University, a leading research institution in Sweden, is dedicated to advancing healthcare through innovative clinical trials and translational research. With a strong emphasis on interdisciplinary collaboration, the university harnesses cutting-edge technology and expert knowledge across various fields to address critical health challenges. Its commitment to ethical standards and patient safety ensures that all clinical trials conducted under its auspices are designed to generate robust scientific evidence, ultimately contributing to improved health outcomes and informed medical practices. Umeå University strives to foster a dynamic research environment that supports the development of new therapies and enhances the understanding of complex health issues.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Uppsala, , Sweden
Göteborg, , Sweden
Stockholm, , Sweden
Linköping, , Sweden
Umeå, , Sweden
Malmö, , Sweden
Patients applied
Trial Officials
Rebecca Wiberg, MD PhD
Principal Investigator
Umeå University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported